Scholarlink

<p><i>Ulva</i> sp. is a green marine macroalga and a promising yet underexplored sustainable food source, with limited research on its allergenicity. This study evaluated the allergenic potential of <i>Ulva</i> sp. demineralized biomass flour (Ulva-DBF) using a weight-of-evidence approach inspired by regulatory assessments for novel foods, combining literature review, proteomic analysis, and a pilot clinical trial. Literature revealed no documented <i>Ulva</i> allergenicity. Proteomic analysis identified a few putative allergens, with estimated allergenic potential below 0.02%. In a pilot clinical trial (registered at ClinicalTrials.gov, Identifier: NCT06452381; First Posted Date: June 11, 2024), 31 participants consumed Ulva-DBF. No allergic reactions occurred, although 16.6% reported gastrointestinal discomfort. These findings represent a preliminary evaluation phase before widespread exposure. Nevertheless, large-scale consumption remains the most effective way to assess public health risks associated with any food. As we seek innovative and sustainable food solutions, post-marketing monitoring is vital to ensure their safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Initial allergenicity assessment of Ulva sp. seaweed flour

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Odeya Kedar,
  • Alexander Golberg,
  • Uri Obolski,
  • Efraim Steinbruch,
  • Alexander Chemodanov,
  • Álvaro Israel,
  • Yoav D. Livney,
  • Idit Lachover-Roth,
  • Yossi Rosman,
  • Ronit Confino-Cohen

摘要

Ulva sp. is a green marine macroalga and a promising yet underexplored sustainable food source, with limited research on its allergenicity. This study evaluated the allergenic potential of Ulva sp. demineralized biomass flour (Ulva-DBF) using a weight-of-evidence approach inspired by regulatory assessments for novel foods, combining literature review, proteomic analysis, and a pilot clinical trial. Literature revealed no documented Ulva allergenicity. Proteomic analysis identified a few putative allergens, with estimated allergenic potential below 0.02%. In a pilot clinical trial (registered at ClinicalTrials.gov, Identifier: NCT06452381; First Posted Date: June 11, 2024), 31 participants consumed Ulva-DBF. No allergic reactions occurred, although 16.6% reported gastrointestinal discomfort. These findings represent a preliminary evaluation phase before widespread exposure. Nevertheless, large-scale consumption remains the most effective way to assess public health risks associated with any food. As we seek innovative and sustainable food solutions, post-marketing monitoring is vital to ensure their safety.